IRLAB Therapeutics Full Year 2024 Earnings: Misses Expectations

IRLAB Therapeutics (STO:IRLAB A) Full Year 2024 Results

Key Financial Results

• Revenue: kr114.1m (up by kr108.4m from FY 2023).
• Net loss: kr83.1m (loss narrowed by 53% from FY 2023).
• kr1.60 loss per share (improved from kr3.43 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

IRLAB Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 56%.

Looking ahead, revenue is expected to decline by 6.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 26%.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are down 7.3% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for IRLAB Therapeutics (2 can't be ignored) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.